These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27031469)

  • 1. Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.
    Beach TG; Thal DR; Zanette M; Smith A; Buckley C
    J Alzheimers Dis; 2016 Mar; 52(3):863-73. PubMed ID: 27031469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of amyloid distribution by [
    Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
    Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
    de Lartigue J
    Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrequent false positive [
    Ikonomovic MD; Fantoni ER; Farrar G; Salloway S
    Alzheimers Res Ther; 2018 Jun; 10(1):60. PubMed ID: 29935545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
    Wolk DA; Grachev ID; Buckley C; Kazi H; Grady MS; Trojanowski JQ; Hamilton RH; Sherwin P; McLain R; Arnold SE
    Arch Neurol; 2011 Nov; 68(11):1398-403. PubMed ID: 21747004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?
    Catafau AM; Bullich S; Seibyl JP; Barthel H; Ghetti B; Leverenz J; Ironside JW; Schulz-Schaeffer WJ; Hoffmann A; Sabri O
    J Nucl Med; 2016 Nov; 57(11):1740-1745. PubMed ID: 27363836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions.
    Cho SH; Choe YS; Kim YJ; Kim HJ; Jang H; Kim Y; Kim SE; Kim SJ; Kim JP; Jung YH; Kim BC; Lockhart SN; Farrar G; Na DL; Moon SH; Seo SW
    J Alzheimers Dis; 2020; 76(1):281-290. PubMed ID: 32474468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging.
    Beach TG; Sue LI; Walker DG; Sabbagh MN; Serrano G; Dugger BN; Mariner M; Yantos K; Henry-Watson J; Chiarolanza G; Hidalgo JA; Souders L
    J Alzheimers Dis; 2012; 28(4):869-76. PubMed ID: 22112552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.
    Leinonen V; Rinne JO; Wong DF; Wolk DA; Trojanowski JQ; Sherwin PF; Smith A; Heurling K; Su M; Grachev ID
    Acta Neuropathol Commun; 2014 Apr; 2():46. PubMed ID: 24755237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
    Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
    Curtis C; Gamez JE; Singh U; Sadowsky CH; Villena T; Sabbagh MN; Beach TG; Duara R; Fleisher AS; Frey KA; Walker Z; Hunjan A; Holmes C; Escovar YM; Vera CX; Agronin ME; Ross J; Bozoki A; Akinola M; Shi J; Vandenberghe R; Ikonomovic MD; Sherwin PF; Grachev ID; Farrar G; Smith AP; Buckley CJ; McLain R; Salloway S
    JAMA Neurol; 2015 Mar; 72(3):287-94. PubMed ID: 25622185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PET-based stages of amyloid deposition with neuropathological markers of Aβ pathology.
    Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):29-42. PubMed ID: 33137247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
    Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
    Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
    Clark CM; Pontecorvo MJ; Beach TG; Bedell BJ; Coleman RE; Doraiswamy PM; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Arora A; Carpenter AP; Flitter ML; Joshi AD; Krautkramer MJ; Lu M; Mintun MA; Skovronsky DM;
    Lancet Neurol; 2012 Aug; 11(8):669-78. PubMed ID: 22749065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.